Blue Trust Inc. Has $105,000 Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Blue Trust Inc. lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 83.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 255 shares of the company’s stock after selling 1,296 shares during the quarter. Blue Trust Inc.’s holdings in IDEXX Laboratories were worth $105,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FSA Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. lifted its position in IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after acquiring an additional 57 shares during the last quarter. Ashton Thomas Securities LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth about $37,000. Retirement Wealth Solutions LLC bought a new position in IDEXX Laboratories in the 4th quarter worth approximately $31,000. Finally, Crews Bank & Trust acquired a new stake in shares of IDEXX Laboratories in the fourth quarter worth $41,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insiders Place Their Bets

In related news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 13,330 shares of company stock worth $6,161,276 over the last 90 days. Corporate insiders own 2.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on IDXX shares. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Bank of America lifted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Morgan Stanley dropped their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Leerink Partners began coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective on the stock. Finally, Piper Sandler raised their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Stock Performance

IDXX stock opened at $452.77 on Friday. The firm has a market cap of $37.08 billion, a PE ratio of 42.43, a P/E/G ratio of 3.41 and a beta of 1.37. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The business has a 50 day moving average of $431.92 and a 200-day moving average of $452.40. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.